Unravelling CYP4V2: Clinical features, genetic insights, pathogenic mechanisms and therapeutic strategies in Bietti crystalline corneoretinal dystrophy

On June 5, 2025, Professor Yang Lili's team from Peking University Third Hospital, in collaboration with Professor Zhang Qingjiong's team from Zhongshan Ophthalmic Center, Professor Vinit B. Mahajan's team from Stanford University, and CHIGENOVO Co., Ltd., published a review titled "Unravelling CYP4V2: Clinical features, genetic insights, pathogenic mechanisms and therapeutic strategies in Bietti crystalline corneoretinal dystrophy" in Progress in Retinal and Eye Research, the top-tier review journal ranked first globally in terms of impact factor in ophthalmology.

Progress in Retinal and Eye Research, as the journal with the highest influence in the international ophthalmology field, annually invites a select few top experts within the field to write systematic reviews. Professor Yang Liping's team has been dedicated to the research and treatment of Bietti's Crystalline Dystrophy (BCD) for many years, delving into the pathogenesis and gene therapy of BCD, and has been invited to publish a BCD review in this journal.

This review comprehensively analyzes the latest research progress on the clinical features, genetic characteristics, pathogenesis, animal models, and treatment strategies of BCD. It also introduces the mechanism of action and significant efficacy of ZVS101e, a drug independently developed by CHIGENOVO, providing a reference for the diagnosis of BCD, the development of therapeutic drugs, and the translation into clinical trials.